Table 2.
Characteristics of the patients included in the individual patient data analysis
| Variables | Overall cohort (N = 286) | ||
|---|---|---|---|
| Nebulized heparin (N = 139) | Control (N = 147) | SD (%), P | |
| Age, years | 50.0 (36.0–69.0) | 45.0 (31.0–63.0) | 17.6, 0.09 |
| (N = 139) | (N = 147) | ||
| Gender, male (%) | 81 (65.9) | 107 (72.8) | −19.0, 0.14 |
| APACHE III | 22.0 (17.0–31.0) | 24.0 (15.0–32.0) | 5.1, 0.74 |
| (N = 57) | (N = 39) | ||
| % TBSA | 25.5 (12.9–52.2) | 31.2 (16.5–52.2) | −5.1, 0.51 |
| (N = 90) | (N = 110) | ||
| Dosage of heparin (U/day) | 30,000 | 0.0 | – |
| (30,000–100,000) | (0.0–0.0) | ||
| Dosage of NAC (mg/day) | 3600 (3600–3600) | 0.0 (0.0–0.0) | – |
| Duration of treatment | 7.0 (3.0–12.0) | 0.0 (0.0–0.0) | – |
| Baseline LIS | 2.0 (0.7–2.5) | 2.0 (1.2–3.0) | −26.2, 0.29 |
| (N = 41) | (N = 39) | ||
| Baseline PaO2/FiO2 | 219.5 (158.2–316.5) | 270.0 (163.5–366.5) | −18.3, 0.09 |
| (N = 136) | (N = 141) | ||
Values are median (IQR) or no./total no. (%). Not all requested data were available for each study
SD standardized difference, TBSA total burn surface area, NAC N-acetylcysteine, LIS lung injury scores, N number of patients